New drug combo aims to shrink HER2 breast tumors before surgery

NCT ID NCT07246317

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding an experimental immunotherapy (QL1706) to standard chemotherapy and targeted drugs can better eliminate HER2-positive breast cancer before surgery. About 188 people with early or locally advanced disease will be randomly assigned to receive either the new combo or standard chemo plus targeted therapy. The main goal is to see if more patients have no cancer left at surgery (pathological complete response).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QL1706 injection (an experimental immunotherapy) combined with trastuzumab, pertuzumab, and docetaxel
What this could lead to: If it works, this could offer a more effective pre-surgery treatment option for HER2-positive breast cancer, potentially improving long-term outcomes.
What could go wrong: This is an early phase 2 trial with only 188 participants, so results may not apply to everyone. Adding QL1706 could also increase side effects like immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Affiliated Hospital of Jiaxing University

Jiaxing, Zhejiang, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China
Nanyang Central Hospital

Nanyang, Henan, China
The First Affiliated Hospital of Henan University of Science & Technology

Luoyang, Henan, China
The First Affiliated Hospital, Sun Yat-sen University (FAH-SYSU)

Guangzhou, Guangdong, China
The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, China
The West China Second University Hospital of Sichuan University (WCSUH- SCU)

Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.